Virginia
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Asian or Pacific Islander individuals in Virginia are least likely to be diagnosed early
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Virginia is 51.2, which is significantly lower than the national rate of 52.8.
- It ranks 17th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Virginia improved by 8%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) is 29.7% nationally.
- Virginia is one of 12 states for which survival data is not available because cases are not tracked after diagnosis.
Early Diagnosis:
- In Virginia, 28.1% of cases are caught at an early stage, which is not significantly different than the national rate of 28.1%.
- It ranks 30th among the 50 states with data on diagnosis at an early stage, placing it in the average tier.
- Over the last five years, the early diagnosis rate in Virginia improved by 13%.
Lung Cancer Treatment
Biomarker Coverage:
- Virginia has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Virginia ranked 23rd (out of the 49 states with available data) with 20.1% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 20.7% and puts Virginia in the average tier.
- Over the last five years, the percent of cases undergoing surgery in Virginia did not change significantly.
No Treatment:
- Virginia ranked 4th (out of the 49 states with available data) with 15.8% of cases not receiving any treatment.
- This is significantly lower than the national rate of 21.0% and puts Virginia in the top tier.
- Over the last five years, the percent of cases receiving no treatment in Virginia did not change significantly.
Screening
Screening for High Risk:
- In Virginia, 18.4% of those at high risk were screened.
- This was not significantly different than the national rate of 18.2%.
- Virginia ranks 26th among all states, placing it in the average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in Virginia is 10.9%.
- This is not significantly different than the national rate of 11.4%.
- Virginia ranks 19th among all states, placing it in the average tier.
Radon Exposure:
- In Virginia, 25.2% of radon test results were at or above the EPA action level.
- It ranks 28th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 53.6 per 100,000 population among Black individuals in Virginia, not significantly different than the rate of 54.2 among Black individuals nationally, and not significantly different than the rate of 53.7 among white individuals in Virginia.
- Survival rates by race and ethnicity are not available for Virginia at this time. Nationally, the five-year survival rate among Black individuals is 27.1%, 9% lower than among white Americans.
- 24.3% of lung cancer cases are diagnosed at an early stage among Black individuals in Virginia, not significantly different than the rate of 25.1% among Black individuals nationally, and significantly lower than the rate of 29.4% among white individuals in Virginia.
- 17.3% of Black individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 17.1% among Black individuals nationally, and significantly lower than the rate of 20.6% among white individuals in Virginia.
- 16.6% of Black individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 15.7% among white individuals in Virginia.
Latino individuals:
- The rate of new lung cancer cases is 20.5 per 100,000 population among Latino individuals in Virginia, significantly lower than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 53.7 among white individuals in Virginia.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 26.2% of lung cancer cases are diagnosed at an early stage among Latino individuals in Virginia, not significantly different than the rate of 23.9% among Latino individuals nationally, and not significantly different than the rate of 29.4% among white individuals in Virginia.
- 22.3% of Latino individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 21.4% among Latino individuals nationally, and not significantly different than the rate of 20.6% among white individuals in Virginia.
- 14.3% of Latino individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 25.8% among Latino individuals nationally, and not significantly different than the rate of 15.7% among white individuals in Virginia.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 27.9 per 100,000 population among Asian or Pacific Islanders individuals in Virginia, significantly lower than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 53.7 among white individuals in Virginia.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 21.5% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Virginia, not significantly different than the rate of 23.7% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 29.4% among white individuals in Virginia.
- 21.8% of Asian or Pacific Islander individuals with lung cancer in Virginia underwent surgery, significantly lower than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 20.6% among white individuals in Virginia.
- 16.2% of Asian or Pacific Islander individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 19.8% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 15.7% among white individuals in Virginia.
Indigenous Peoples:
- The rate of new lung cancer cases is 23.5 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Virginia, significantly lower than the rate of 39.8 among Indigenous Peoples nationally, and significantly lower than the rate of 53.7 among white individuals in Virginia.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Virginia due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Virginia falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Virginia has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Virginia falls into the top tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
